Health Canada Approves MAVIRET® 8-Week Treatment Duration for Treatment-Naïve Patients with Genotype 3 Compensated Cirrhosis

  • MAVIRET ® (glecaprevir/pibrentasvir) is the only 8-week oral treatment approved for all Hepatitis C virus (HCV) Genotypes. 1
  • MAVIRET is indicated for the treatment of chronic HCV infection in adults and adolescent patients 12 to 18 years of age . 1
  • MAVIRET is available and reimbursed across Canada . **

ABBVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that Health Canada has approved a label change for MAVIRET ® (glecaprevirpibrentasvir tablets) to include Treatment-Naïve Genotype 3 patients with compensated cirrhosis. 1 With this change, the recommended treatment duration for ALL individuals* with chronic hepatitis C virus (HCV) infection who are treatment naïve, genotypes 1-6 withor without compensated cirrhosis is 8 weeks.

MAVIRET® (glecaprevir/pibrentasvir) product shot – source AbbVie Canada. (CNW Group/AbbVie Canada)

"I witness the destructive effects hepatitis C has on patients, our community and healthcare system.  At the Ottawa Hospital, we see thousands of people on a yearly basis with a variety of liver diseases.  Having access to effective HCV treatment options that cover all hepatitis C genotypes is a game changer," said Dr. Curtis Cooper , Director, The Ottawa Hospital and Regional Hepatitis Program.  "We now have an opportunity to eliminate this deadly virus with testing, treatment and care in shorter periods of time also available for patients with Genotype 3."

"In 2016, Canada committed on the world stage to eliminate viral hepatitis by 2030.  In order to accomplish this important goal, we need population-specific strategies that include equitable access to scaled-up testing and treatment," said, Gerard Yetman , Chair, Action Hepatitis Canada (AHC).  "If we want to eliminate hepatitis C in Canada , we need public access to effective treatment options that cover all genotypes."

Health Canada first approved MAVIRET in August 2017.  MAVIRET is a once-daily ribavirin-free treatment for adults and adolescent patients 12 to 18 years of age with chronic hepatitis C virus infection across all major HCV genotypes (GT1-6). 2 It is an 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment.*

MAVIRET's efficacy and safety were evaluated in nine phase II-III clinical trials, in over 2300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis). 1

"AbbVie is committed to eliminating hepatitis C by 2030 and sees this objective as a national public health priority.  Through meaningful partnerships, we are working to find sustainable solutions that allow more patients to be screened, linked to care, and treated sooner," said Denis Hello, Vice-President and General Manager AbbVie Canada.

About Hepatitis C
An estimated 250,000 people in Canada are living with chronic hepatitis C but as many as 44% are not aware that they have it. 3 Left undiagnosed and untreated, chronic hepatitis C can lead to cirrhosis, liver cancer or liver failure.  Currently, hepatitis C is the leading indication for liver transplant in Canada . 4 AbbVie supports a range of efforts to help elevate and prioritize HCV elimination because we know achieving the shared goal of elimination by 2030 will take more than medicine. It will take transparent and collaborative partnerships with all stakeholders – industry, healthcare providers, healthcare systems, patient groups and their support networks. Joint efforts and maximizing the time we have left will enable us to reach this goal.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com . Follow @abbviecanada on Twitter or find us on Facebook , LinkedIn and Instagram .

* The safety and efficacy of MAVIRET in patients less than 12 years of age have not been established. MAVIRET exposures in HCV-infected patients 12 to 18 years were comparable to those in HCV-infected adults; however, the safety and efficacy of MAVIRET in patients 12 to 18 years infected with HCV genotype 5 or 6 and/or with compensated cirrhosis and/or previously treated with a regimen containing NS5B inhibitor have not been studied.

** Please refer to your province's or Territory's specific reimbursement criteria.

_____________________________

1 AbbVie Corporation MAVIRET (glecaprevir/pibrentasvir tablets) Product Monograph. Date of Preparation: August 16, 2017. Date of Revision: October 30, 2020 .

2 CADTH Canadian Drug Expert Committee Recommendation –Final. www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf . Accessed September 2020.

3 Canadian Network on Hepatitis C (CanHepC). Blueprint to inform hepatitis C elimination efforts in Canada. https://www.canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf Accessed September 2020. 4 The

4 Canadian Liver Foundation. www.liver.ca/how-you-help/advocate/ . Accessed September 2020.

SOURCE AbbVie Canada

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/November2020/10/c6230.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets. Data was sourced from ETFdb.com on March 1, 2024, and all data was current as of that time.

Keep reading...Show less

Latest Press Releases

Related News

×